

Sheet

PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

of

(use as many sheets as necessary)

Application Number 10/655,873

Filing Date September 5, 2003

First Named Inventor Shyam S. Mohapatra

Group Art Unit 1632

Examiner Name Louis D. Lieto

Attorney Docket Number USF-182XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W	R1	KUMAR, M. et al. "IFN-γ and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy" J. Allergy Clin Immunol., September 2001, 108:402-408.	
	R2	NONAKA, M. et al. "Induction of eotaxin production by interleukin-4, interleukin-13 and lipopolysaccharide by nasal fibroblasts" Clin. Exp. Allergy, 2004, 34:804-811.	
و مربع م ود الماعدة - ا	R3	UPTON, C. et al. "Encoding of a homolog of the IFN-γ receptor by myxoma virus" Science, 1992, 258:1369-1372.	
	R4	VANDENBROECK, K. et al. "The conserved helix C region in the superfamily of interferon-γ/interleukin-10-related cytokines corresponds to a high-affinity binding site for the HSP70 chaperone DnaK" J. Biol. Chem., 2002, 277:25668-25676.	
	R5	ZHU, Z. et al. "Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation" Science, 2004, 304:1678-1682.	
	R6	"Immunocytokines – Local Stimulation of the Immune System", 2002, www.merck.at/produkte/immunozytokine.pdf.	
	R7	STALLMACH, A. et al. "An Interleukin 12 p40-lgG2b Fusion Protein Abrogates T Cell Mediated Inflammation: Anti-Inflammatory Activity in Crohn's Disease and Experimental Colitis In Vivo", Gut., 2004, pp. 339-345, Vol. 53.	
	R8		
	R9		
	R10	·	
	R11		
	R12		
	R13		

Examiner Signature Date Considered 9.19.05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

